ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

PRM Proteome Sciences Plc

3.76
0.33 (9.62%)
28 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Proteome Sciences Plc LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.33 9.62% 3.76 3.52 4.00 3.50 3.50 3.50 297,489 16:35:23
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 7.78M 1.33M 0.0045 7.78 10.33M

Proteome Sciences PLC Trading Update (1357V)

30/11/2023 7:00am

UK Regulatory


Proteome Sciences (LSE:PRM)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more Proteome Sciences Charts.

TIDMPRM

RNS Number : 1357V

Proteome Sciences PLC

30 November 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310.

30 November 2023

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Trading update for the year 2023

The Company announces a trading update to its shareholders.

The Company expects the US laboratory to be operational in the coming weeks and is lining up first customer projects for this laboratory. The Company is also engaged in discussions with several pharmaceutical companies and academic groups regarding single cell proteomics projects and hope to initiate studies early in 2024.

However, the Company now expects to report reduced revenues for the full year 2023, which will be lower than FY 2022. As reported by many other life science technology providers, the Company has experienced delays to projects, many of which have been postponed to 2024. The healthcare industry has faced a very challenging market environment this year, especially in the second half of the year. In addition to other topical macro-economic headwinds, the Company has seen that the biopharma clients have been restrictive on R&D outsourcing expenditure through contract research organisations.

Reduced revenues combined with the commitment to invest for the future by opening the Company's US laboratory, developing and commercial launch of Single Cell Proteomics, and the development of next generation tags, means the Company expects to post a net loss for the full year 2023.

For 2024 the Company expects a more positive environment for services evidenced by increased customer activity in recent weeks and based on the expectation that an improved macro-economic environment will drive renewed investment into drug development at more traditional levels and that delayed projects will be commissioned.

Proteome Sciences plc

 
Dr. Mariola Soehngen, Chief Executive Officer   Tel: +44 (0)20 7043 2116 
 Dr. Ian Pike, Chief Scientific Officer 
Richard Dennis, Chief Commercial Officer 
 Abdelghani Omari, Chief Financial Officer 
 
Allenby Capital Limited (Nominated Adviser & Broker) 
John Depasquale / Jeremy Porter (Corporate      Tel: +44 (0) 20 3328 5656 
 Finance) 
 Stefano Aquilino / Tony Quirke (Sales & 
 Corporate Broking) 
 
 

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R)MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TSTUKSRROKUAUUA

(END) Dow Jones Newswires

November 30, 2023 02:00 ET (07:00 GMT)

1 Year Proteome Sciences Chart

1 Year Proteome Sciences Chart

1 Month Proteome Sciences Chart

1 Month Proteome Sciences Chart

Your Recent History

Delayed Upgrade Clock